Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.
- 1 January 1999
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 16 (4) , 379-397
- https://doi.org/10.2165/00019053-199916040-00006
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinomaCancer, 1997
- A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast CancerPharmacoEconomics, 1996
- THE COSTS OF TREATING BREAST CANCER IN AUSTRALIA AND THE IMPLICATIONS FOR BREAST CANCER SCREENINGAnz Journal of Surgery, 1995
- ABC of Breast Diseases: Metastatic breast cancerBMJ, 1994
- Determining Transition ProbabilitiesMedical Decision Making, 1994
- Advanced breast cancer: use of resources and cost implicationsBritish Journal of Cancer, 1993
- Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of lifeBritish Journal of Cancer, 1993
- The cost of breast cancer recurrencesBritish Journal of Cancer, 1992
- Endocrine Treatment of Breast Cancer in WomenEndocrine Reviews, 1990
- Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group StudyCancer, 1984